Current stock page

Stock Analysis

Inhibrx Biosciences Inc. (INBX) Stock Analysis

Inhibrx Biosciences Inc. (INBX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

INBX Stock Analysis Summary

Inhibrx Biosciences Inc. (INBX) currently has an AIQ Score of 40/100, indicating a bearish setup. Momentum is the strongest factor at 50/100. Quality is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

INBX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$83.30
AIQ Score40/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$1.31B
P/E Ratio (TTM)-9.19
Forward P/E—
EPS (Q3 FY2026)-$2.46
Revenue (Q3 FY2026)$2M
Dividend Yield (TTM)0.00%
Beta2.18
Volume245.9K
52-week range$57.30-$155.29
RSI 1445.11
50-Day SMA$95.27
200-Day SMA$92.69
Analyst Price Target$245.00
Next Earnings—
As of Nov 13, 2026 · Market close

INBXInhibrx Biosciences Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 6/10
$83.30−$4.45 (−5.07%)

Latest quote

  • Momentum
    50
  • Value
    —
  • Quality
    28
  • Risk resilience
    40
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

INBX Stock Analysis Summary

Inhibrx Biosciences Inc. (INBX) currently has an AIQ Score of 40/100, indicating a bearish setup. Momentum is the strongest factor at 50/100. Quality is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, INBX has AIQ Score of 40/100 with Momentum base of 50/100 and fading Quality at 28/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (50/100) leads while Quality (28/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -5.07% stock move · INBX classified in Biotechnology.

Current Evidence

BearishINBX is in a bearish AIQ regime; Momentum is the strongest visible factor at 50/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is INBX Bullish or Bearish Right Now?

INBX currently has a bearish overall setup. Momentum is the strongest factor at 50/100, while Quality is weakest at 28/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +194.12% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 40/100.
  • - Price is -10.13% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (32 vs 6).

Current Consensus

INBX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 8 neutral, and 32 sell votes. INBX's 14-day RSI is 45.11, which places the stock in a neutral momentum range. INBX's beta is 2.18, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in INBX?

The largest recent change in INBX is Momentum moving up by 12.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+3.0
Momentum
+12.0
Quality
-9.0
Risk
+6.0

What Would Change the INBX Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

INBX Decision Framework

Public evidence layers, setup checks, and risk context for Inhibrx Biosciences Inc..

Inhibrx Biosciences Inc. (INBX) Stock Analysis

Inhibrx Biosciences Inc. has an AIQ Score of 40/100 in a Bearish regime. Momentum is strongest at 50/100. Beta is 2.18, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextINBX is in a Bearish AIQ regime with score 40/100.
Signal ConflictThe primary conflict is that momentum leads at 50/100 while quality lags at 28/100.
Factor EvidenceMomentum 50/100 · Quality 28/100 · Risk 40/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Momentum is the strongest factor at 50/100.

TimingWait

Momentum is 50/100 and RSI (14) is 45.1.

Regime fitFail

INBX is in a Bearish regime at 40/100.

Risk controlFail

Risk factor is 40/100 with beta 2.18 and annual volatility 82.28%.

ConflictWait

Current conflict: momentum leads at 50/100 while quality lags at 28/100.

AIQ Score
40/100
Price
$83.30
Beta
2.18
RSI (14)
45.1

INBX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

INBX Fundamentals

INBX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$2M
Net income
-$38.73M
Free cash flow
-$34.66M
View full INBX fundamental analysis

INBX Technical Analysis

INBX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
45.11
Price vs SMA-50
-12.56%
View full INBX technical analysis

INBX Stock Catalysts

Track INBX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
—
Analyst target
$245.00
News items
4
View INBX earnings and stock catalysts

INBX Dividend Analysis

INBX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
1.02%
Annual dividend
$0.85
Payout ratio
—
View INBX dividend history and analysis

INBX Financial Data

INBX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$2M
EPS
-$2.46
Periods
8
View INBX financials

INBX Risk Analysis

INBX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
2.18
Risk score
40/100
1Y volatility
82.28%
View INBX risk analysis

INBX Stock News

INBX stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read INBX stock news

INBX vs Biotechnology Peers

Current peer cohort: INBX · INSM · INVA · IRON · JAZZ. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
INBX
Current stock
40/100—50/10040/1000.4982.28%Current
INSM
Insmed Incorporated
57/10055/10061/10049/100-0.4863.12%INBX vs INSM
INVA
Innoviva, Inc.
67/10092/10043/10074/100-0.6425.21%INBX vs INVA
IRON
Disc Medicine, Inc.
65/100—75/10051/1000.163.55%INBX vs IRON
JAZZ
Jazz Pharmaceuticals plc
73/10079/10066/10073/1001.4738.64%INBX vs JAZZ
Pairwise Compare links: INSM · INVA · IRON · JAZZINBX vs INSMINBX vs INVAINBX vs IRONINBX vs JAZZCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a INBX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for INBX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-9.19
As of Nov 13, 2026
Revenue growth
—
Gross margin
-55.05%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$2M
Quarter net income
-$38.73M
Quarter free cash flow
-$34.66M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
45.11
MACD
-2.14

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
40/100
Beta
2.18
Annual volatility
82.28%
Max drawdown
-49.39%

INBX Stock FAQ

What is INBX stock price today?

Inhibrx Biosciences Inc.'s current stock price is $83.30. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is INBX bullish or bearish right now?

INBX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is INBX's market cap?

INBX's market cap is $1.31B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is INBX's current P/E ratio?

INBX's current P/E ratio is -9.19 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is INBX's RSI?

INBX's 14-day RSI is 45.11 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is INBX above its 50-day and 200-day moving averages?

INBX is -12.56% from its 50-day SMA and -10.13% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is INBX's next earnings date?

INBX's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does INBX pay a dividend?

INBX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.